Lu Zhou > Hogan Lovells International LLP > Beijing, China > Lawyer Profile

Adopting a strategic sector focus on the TMT, life sciences and healthcare sectors, Hogan Lovells International LLP’s private equity practice works in conjunction with PRC law firm Fujan Fidelity Law Firm to offer clients fully integrated international and domestic Chinese legal advice. Heading the private equity group for Greater China from Hong Kong is Stephanie Tang, whose expertise covers the spectrum of transactions including LBOs, take-privates, de-SPACs, PIPEs and equity investments. Don Williams is a vastly experienced contact in Shanghai, having recently led when advising Ping An as lead investor on the $100m initial closing of the Series E financing of Visby Medical, a developer of PCR-based diagnostics tests for infectious disease detection. Also in Shanghai, Tony Mou is a trusted advisor to PE and VC funds, entrepreneurs, venture-backed growth stage and public companies, while Beijing-based Lu Zhou brings deep industrial regulatory knowledge to help clients navigate complex structuring and operational issues.

In addition to assisting foreign clients with inbound matters, Hogan Lovells International LLP‘s Greater China M&A practice acts for Chinese clients on their investments abroad. The team is particularly experienced in TMT, financial services, manufacturing and automotive-related deals. Clients also appreciate the firm’s transatlantic transactional strength, which facilitates access to over 500 M&A lawyers in more than 45 offices globally. The practice also provides integrated international and domestic Chinese legal advice through its association with PRC law firm Fidelity Law Firm. In Beijing, Liang Xu‘s track record includes numerous cross-border joint ventures and M&A deals, while Lu Zhou is experienced in advising clients from the TMT, life sciences and education sectors. In the Shanghai office, Don Williams acts for private and public companies on cross-border M&A, minority investments and other strategic business transactions, and Tony Mou is a corporate law and transactions specialist. Aldo Boni De Nobili is an experienced senior associate.

Hogan Lovells International LLP offers a wide range of expertise, spanning corporate and finance, IPMT, global regulatory, litigation, and employment. The firm addresses key areas like privacy, cybersecurity, fintech, and blockchain, offering services such as market access analysis, regulatory counsel, and compliance report drafting. Spearheaded by Mark Parsons from Hong Kong, the team includes Sherry Gong, who excels in data privacy, cybersecurity, and e-commerce, guiding multinationals through intricate cross-border undertakings. Don Williams supports TMT companies across all stages from startup to mature public company, encompassing areas such as VC/PE financing and M&A. Tong Zhu specialises in data privacy and e-commerce in China, offering advice on data-related challenges including data localisation and IT structure implications. Flora Feng aids foreign enterprises in navigating regulatory matters in China, notably in cybersecurity and personal data protection arenas, while Lu Zhou represents multinational corporations and PE fund clients in cross-border M&A, venture capital investments, and restructuring.

Offering expertise on regulatory compliance, M&A deals in the life sciences space, sanctions and export controls, and the legal implications of clinical trials, Hogan Lovells International LLP provides a comprehensive service for clients in the Chinese market. The team is jointly led by Roy Zou, who is highly experienced in U.S. litigation matters involving Chinese companies or government agencies as respondents or defendants, and cross-border transactional and financing expert Lu Zhou. The regulatory compliance focussed Calvin Ding, who is experienced in both government sanctioned and internal compliance investigations, is also key, as is life sciences and healthcare sector antitrust expert Adrian Emch. Jessie Xie, who specialises in medical device and pharmaceutical clinical trials and product approval issues, is also well-recommended.